MannKind Completes Enrollment in US Phase 4 Inhale-3 Clinical Trial in Patients Living With Type 1 Diabetes
Portfolio Pulse from Benzinga Newsdesk
MannKind Corporation (NASDAQ:MNKD) has completed enrollment for its INHALE-3, a Phase 4 clinical trial. The trial is evaluating inhaled insulin (combined with basal insulin) versus usual care in adults living with type 1 diabetes.
November 06, 2023 | 11:17 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
MannKind Corporation's completion of enrollment for its Phase 4 clinical trial could potentially accelerate the development and commercialization of its inhaled insulin product.
The completion of enrollment for the Phase 4 clinical trial indicates progress in MannKind's product development. This could potentially lead to faster commercialization of the product, which would be positive for the company's stock.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100